- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04144608
Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
August 12, 2023 updated by: Yongchang Zhang
A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
The aim of the study was to investigate the safety and efficacy of Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yongchang Z MD, MD
- Phone Number: +8613873123436 +8613873123436
- Email: zhangyongchang@csu.edu.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Provincal Tumor Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Previously untreated, histologically confirmed potentially resectable stage IIIA or IIIB (AJCC staging eighth edition) NSCLC; potentially resectable refers to a discussion by the surgeon, including primary T3 or T4, mediastinum Lymph node metastasis (N2) is defined as: single-site or multi-station metastasis can be confirmed by imaging or pathology with a short diameter ≥ 2 cm, and it is expected that resection is difficult or pneumonectomy is required;
- Before the enrollment, submit the PD-L1 immunohistochemistry section and the corresponding pathology report for biomarker evaluation (the tumor tissue sample must be fresh or archived samples obtained within 3 months before enrollment; Fresh tissue must be a needle biopsy, excision or incision biopsy specimen);
Exclusion Criteria:
Patients received Toripalimab before Patients with contraindication of chemotherapy Pregnant or breast feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Toripalimab Combined With Platinum-containing Dual-agent
Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
|
Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 surgical resection rate
Time Frame: Approximately 1 years
|
No residual ratio under the microscope after surgical resection
|
Approximately 1 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Approximately 1 years
|
To measure the patients's overall response rate
|
Approximately 1 years
|
MPR
Time Frame: Approximately 1 years
|
Neoadjuvant therapy-induced tumor regression in pathologically residual tumors <10%
|
Approximately 1 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yongchang Z MD, MD, Hunan Province Tumor Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 16, 2019
Primary Completion (Actual)
June 30, 2022
Study Completion (Actual)
July 30, 2023
Study Registration Dates
First Submitted
October 28, 2019
First Submitted That Met QC Criteria
October 28, 2019
First Posted (Actual)
October 30, 2019
Study Record Updates
Last Update Posted (Actual)
August 15, 2023
Last Update Submitted That Met QC Criteria
August 12, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TOGATHER
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non Small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
-
Gilead SciencesArcus Biosciences, Inc.RecruitingLung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung CancerUnited States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Clinical Trials on Toripalimab combination with platinum-containing dual-drug chemotherapy
-
Peking University Cancer Hospital & InstituteEnrolling by invitationLocally Advanced NSCLCChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting
-
Tang-Du HospitalRecruitingNSCLC Stage IV | OligometastasisChina
-
Fujian Cancer HospitalRecruitingUntreated Advanced Non-small Cell Lung CancerChina
-
Sichuan UniversityInnovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Lung Squamous Cell CarcinomaChina
-
The Second Affiliated Hospital of Shandong First...RecruitingNon-small Cell Lung CancerChina
-
Tongji UniversityRecruiting
-
Bristol-Myers SquibbRecruiting
-
Fudan UniversityZhejiang Cancer Hospital; Fujian Cancer Hospital; The Affiliated Nanjing Drum...Recruiting
-
Sun Yat-sen UniversityRecruiting